 |
|
|
| |
Age-Related Co-Morbidities and Polypharmacy in HCV-Infected Patients With Substance Use Disorders Treated With G/P: A Real-World Analysis From 9 Countries
|
| |
| |
AASLD Nov 11-16 virtual
Reported by Jules Levin
Dominque Larrey1, Massimo Puoti2, Anna Piekarska3, David Back4, Fiona Marra4, Mark Bondin5, Ritu Raheja5, Zhenzhen Zhang5, Hari V Kalluri5, John Marcinak5, Carlos Roncero61Hepato-Gastroenterologie, Hôpital Saint-Eloi, Montpellier, France; 2Niguarda ca Grande Hospital, Milan, Italy; 3Infectious Diseases and Hepatology Department, Medical University of Lodz, Lodz, Poland; 4Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom; 5AbbVie Inc, North Chicago, Illinois, United States; 6Psychiatry Service, University of Salamanca Health Care Complex, Institute of Biomedicine, University of Salamanca, and Psychiatry Unit, School of Medicine, University of Salamanca, Salamanca, Spain
|
| |
|
|
|
|
|
